NEW YORK, NY / ACCESSWIRE / April 11, 2024 /
Palo Alto Networks, Inc. (NASDAQ:PANW)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that between August 18, 2023 and February 20, 2024 the Company made false and/or misleading statements and/or failed to disclose that: (i) the Company's consolidation and platformization initiatives were not driving increased market share to a significant degree; (ii) the Company would need to ramp up platformization and free product offerings to entice customers to adopt more of their platforms; (iii) the Company's high growth in billings was not sustainable; (iv) new AI offerings were not facilitating greater platformization and consolidation; and (v) based on the foregoing, the Company lacked a reasonable basis for their positive statements about customer demand, billings, and platformization, as well as related financial results, growth, and prospects.
If you are a PANW investor and owned the shares during the period of alleged wrongs, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
The Children's Place, Inc. (NASDAQ:PLCE)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that between March 16, 2023 and February 8, 2024the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was engaged in aggressive promotions; (ii) as a result, the Company's inventory values were overstated; (iii) the foregoing was reasonably likely to have an adverse impact on fiscal 2023 financial results; and (iv) as a result of the foregoing, the Company's positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you are a PLCE investor and owned the shares during the period of alleged wrongs, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
Snowflake Inc. (NYSE:SNOW)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that between September 16, 2020 and March 2, 2022 the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Snowflake had systematically oversold capacity to customers which created a misleading appearance of the demand for Snowflake's products and services; (ii) Snowflake had provided significant discounts to its customers prior to its initial public offering ("IPO") that temporarily boosted sales but would not be sustainable after the IPO and/or necessitate platform efficiency adjustments that negatively impacted client consumption and Snowflake's revenue and profit margins; (iii) as a result, Snowflake's customers were poised to roll over a material amount of unused credits (and thereby cannibalize future sales) at the end of their contracts' terms or to refuse to renew their contracts at prior consumption levels or at all; and (iv) consequently, Snowflake's product revenue and remaining performance obligations had been artificially inflated.
If you are a SNOW investor and owned the shares during the period of alleged wrongs, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
Ventyx Biosciences, Inc. (NASDAQ: VTYX)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that between October 21, 2021 and November 6, 2023the Company made materially false and/or misleading statements and/or failed to disclose that: (i) VTX958 was less effective in treating psoriasis than the Company had led investors to believe; (ii) as a result, VTX958's clinical and/or commercial prospects were overstated; (iii) accordingly, the Company had misrepresented its ability to develop and commercialize effective product candidates; (iv) Ventyx's post-IPO business prospects were thus inflated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you are a VTYX investor and owned the shares during the period of alleged wrongs, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
ATTORNEY ADVERTISING.© 2024 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: [email protected]
SOURCE: Lifshitz Law Firm, P.C.